TNYA – tenaya therapeutics, inc. (US:NASDAQ)

News

Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript [Seeking Alpha]
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com